©The Author(s) 2026.
World J Transplant. Mar 18, 2026; 16(1): 111959
Published online Mar 18, 2026. doi: 10.5500/wjt.v16.i1.111959
Published online Mar 18, 2026. doi: 10.5500/wjt.v16.i1.111959
Table 2 Unadjusted outcomes in basiliximab vs alemtuzumab, n (%)/median (interquartile range)
| Outcomes | Basiliximab (n = 160) | Alemtuzumab (n = 102) | Total (n = 262) | P value |
| One-year estimated glomerular filtration rate | 53.5 (42.0-65.0) | 46.5 (34.0-54.8) | 50.0 (40.0-62.0) | < 0.001 |
| Cytomegalovirus viremia | 21 (13.2) | 31 (30.4) | 52 (19.9) | < 0.001 |
| Epstein-Barr virus viremia | 6 (3.8) | 11 (10.8) | 17 (6.5) | 0.025 |
| BK viremia | 18 (11.3) | 21 (20.6) | 39 (14.9) | 0.040 |
| Acute rejection throughout the follow up period | 10 (7.6) | 19 (18.6) | 29 (12.4) | 0.012 |
| Post-transplant glomerulonephritis | 5 (3.2) | 4 (3.9) | 9 (3.5) | 0.744 |
| Post transplant malignancy | 6 (4.3) | 12 (11.9) | 18 (7.5) | 0.027 |
- Citation: Chukwu CA, Kalra PA, Lowe M, Poulton K, Augustine T, Rao A. Outcomes of basiliximab vs alemtuzumab induction in kidney allograft recipients with matched immunological Profiles: A retrospective cohort study. World J Transplant 2026; 16(1): 111959
- URL: https://www.wjgnet.com/2220-3230/full/v16/i1/111959.htm
- DOI: https://dx.doi.org/10.5500/wjt.v16.i1.111959